Skip to main content

Case reports of cerebral sinus venous thrombosis in COVID-19 patients



Coronavirus disease 2019 (COVID-19) pandemic has started in December 2019 and still ongoing. The disease has been expanding rapidly with a high variety of phenotypes from asymptomatic, mild respiratory tract infection, multiple organ system dysfunction, and death. Neurological manifestations also appear in patients with COVID-19, such as headache, seizures, a decrease of consciousness, and paralysis. The hypercoagulable state in patients with COVID-19 is associated with the thromboembolic incident including ischemic strokes, venous thromboembolism, pulmonary artery embolism, and many further. Cerebral sinus venous thrombosis (CSVT) is a rare neurovascular emergency that is often found in critically ill patients. We report two cases of CSVT with different onsets, neurologic manifestations, and prognoses.

Case presentation

Two cases of cerebral sinus venous thrombosis in COVID-19 patients were reported, following respiratory, hematology, and coagulation disarrangements, which was triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The first patient, which was presented with a seizure, had hypertension and diabetes mellitus as comorbidities. The latter case had no comorbidity but showed more severe presentations of COVID-19 such as brain and lung thrombosis, although already had several days of intravenous anticoagulant administrations. These two cases also have a different course of disease and outcomes, which were interesting topics to study.


CSVT is one of the neurological complications of the COVID-19 when the brainstem venous drainage is involved. Despite successful alteration to the negative result of SARS-CoV-2 through the rt-PCR test, thrombogenesis and coagulation cascade continuing. Therefore, a high level of neutrophil to lymphocyte ratio (NLR), D-dimer, fibrinogen, and C-reactive protein (CRP) are paramount indicators of poor prognosis.


In December 2019, the cases of SARS-CoV-2 infection have been observed to cause severe pneumonia, in Hubei Province, China [1]. Several studies have described the clinical manifestation in COVID-19 including fever, cough, malaise, dyspnea, and decrease of consciousness [2,3,4]. COVID-19 involvement in the nervous system was also reported with cerebrovascular disease, headache, impaired consciousness, seizure, impairment of smell, and skeletal muscle injury [5]. Critically ill patients are prone to have neurological manifestations with some comorbidities of older age, hypertension, diabetes, and/or cardiac disease [5]. Ischemic and hemorrhagic stroke also reported as cerebrovascular disease (CVD) in severe COVID-19 [6]. The CVS in COVID-19 may be due to high levels of hypercoagulable state after the cytokine storm. Massive thrombosis in COVID-19 patients may occlude the venous system in the brain that ended with cerebral sinus venous thrombosis (CSVT) [7,8,9]. The CSVT is a rare neurovascular emergency but further investigation in these cases may help to prevent the delay in diagnosing and treating these cases in the COVID-19 pandemic.

We reported two cases of concomitant CSVT and COVID-19 infection. The patients developed a profound neurological injury, secondary to CSVT, with SARS-CoV-2 infection confirmed by the reverse transcriptase-polymerase chain reaction (rt-PCR) test. The SARS-CoV-2 virus activates the inflammatory cascade and thrombotic pathways, by binding angiotensin-converting enzyme 2 (ACE2) receptors of endothelial cells [10]. This leads to a hypercoagulable state, proved by the increase of D-dimer [3, 11]. Furthermore, the increased level of D-dimer indicates high thrombus formation [12], although two cases of CSVT were having a neurological manifestation of COVID-19.

Case presentation

On the 5th of August, 2020, a 58-year-old woman presented in our emergency department with seizures and hemiparesis. She had a prior fever, malaise, and dry cough a week before admission. She has had a history of hypertension since a year ago. The vital sign is within normal limit except the blood pressure is 170/110 mmHg.

The results of the laboratory test were high blood glucose 254 mg/dL and HbA1C 6.5%. Leukocytosis with white blood cells (WBC) was 14/L and neutrophil-lymphocyte ratio (NLR) was 33. Increase level of erythrocyte sedimentation rate (ESR) 93 mm/h, D-dimer 21,176 ng/mL, and fibrinogen 446 mg/dL. The result of the reverse transcription-polymerase chain reaction (rt-PCR) test from the nasal swab was observed to be positive for SARS-CoV-2. The completed laboratory results are listed in Table 1

Table 1 Summary of laboratory findings at admission

Head contrast computed tomography (HCCT) showed cerebral edema at the right parietal lobe (Fig. 1B). There were hyperdense veins and sinuses at the right parietal lobe area, superior sagittal sinus (SSS), and bilateral transverse sinuses (TS), which suggested the presence of a cerebral sinus venous thrombosis (CSVT) (Fig. 1B–D), with a sign of venal hypertension. CT venography (CTV) was also confirmed CSVT at SSS, bilateral TS, and bilateral sigmoid sinus (Fig. 1E, F). Furthermore, the thorax CT scan showed ground-glass opacity and subpleural bilateral, with a fibrotic appearance in the left lung (Fig. 1A).

Fig. 1
figure 1

Acute onset of cerebral sinus venous thrombosis in COVID-19. A Axial thorax CT-scan showed ground-glass opacity and subpleural bilateral, with a fibrotic appearance in the left lung. B Axial head non-contrast CT-scan (NCCT scan) showed, parenchymal edema on the right parietal lobe and hyperdense cortical veins. C Sagittal NCCT scan showed parenchymal edema on the right parietal lobe and hyperdense superior sagittal sinus. D Coronal head NCCT scan showed parenchymal edema on the right parietal lobe and hyperdense superior sagittal sinus. E, F Brain CT venography showed, filling defect at SSS, TS bilateral, sigmoid sinus bilateral

During the patient’s treatment of COVID-19, 60 mg subcutaneous enoxaparin was administered twice daily, for 5 days. On the 5th day of treatment, D-dimer was decreased to 2092 ng/ml. The decision was made to continue with enoxaparin until the normal D-dimer or the patient’s negative status for the COVID-19 virus is attained. Other clinical manifestations also improved and the patient was discharged from the hospital on the 10th day.

The second case, a 72-year-old male, was consulted from the intensive care unit (ICU) because of sudden decreases in consciousness. He had a history of high fever, dry cough, and shortness of breath a week before hospitalization. The patient was being treated as severe COVID-19 with ARDS for 10 days in ICU. He had no previous history of hypertension, diabetes mellitus, or cardiovascular disease. He already received heparin intravenously for 10 days and halted, due to good recovery of shortness of breath and hypoxemia. A day after heparin cessation, the patient suddenly unconscious and intubated due to severe hypoxia.

Upon examination, his consciousness is coma with a slow response to the light of both eyes. He had hypothermia with a temperature of 35.4 °C, blood pressure of 140/69 mmHg on vasoconstrictor epinephrine support, and 90% oxygen saturation.

Laboratory test showed, critical increase level of WBC (53.09 × 103/L) and NLR 58.1. We did not do a peripheral blood smear to examine any hematological disorder. Coagulation function tests were APTT 20.2 s, PT 11.9 s, INR 1.11, D-dimer 5.308 ng/mL (previous was > 50,000), and fibrinogen 525 mg/dL. The rt-PCR test from a nasopharyngeal swab sample was negative for SARS-CoV-2 on the 11th day. The laboratory results are listed in Table 1.

Head non-contrast computed tomography (NCCT) showed hyperdense at superior sagittal sinus and right transverse sinuses, which suggested the manifestations of CSVT (Fig. 2A–C). Furthermore, there was associated cerebral edema at the left frontal, parietal lobe, and cerebellum (Fig. 2B). Thorax CT scan showed ground-glass opacity and subpleural bilateral with the fibrotic appearance in both lung and pulmonary angiography. Thrombosis at segments 8 and 9 of both lungs was also observed (Fig. 2D). The pulmonary CT-angiography (CTA) results were pulmonary embolism and thrombosis of both the left and right pulmonary arteries. Due to the massive thrombosis, a decision was made to administer streptokinase and heparin, to the patient intravenously. After 3 days of this treatment, the patient became desaturated (40% oxygen saturation) with spontaneous pneumothorax and passed away the next day.

Fig. 2
figure 2

Subacute onset of cerebral sinus venous thrombosis in a man with COVID-19 and ARDS. A Sagittal head NCCT scan showed hyperdense at superior sagittal sinus and right transverse sinuses. B Axial head NCCT scan showed hyperdense at superior sagittal sinus (white arrow) and brain parenchymal edema on the left parietal lobe. C Axial head NCCT scan showed hyperdense at right transverse sinus (white arrow). D Axial thorax CT-scan showed ground-glass opacity and subpleural bilateral, with the fibrotic appearance in both lungs


CSVT is a rare cerebrovascular disease that incidences only 0.5% to 1% of all stroke cases [13,14,15]. CSVT is more common in young individuals, with broad manifestation, depending on the site of the thrombosis [13, 16]. It is concomitant with multiple factors, for example prior medical conditions (thrombophilia, inflammatory bowel disease), transient situations (pregnancy, dehydration, infection), particular medications (oral contraceptives, substance abuse), and unpredictable events (head trauma) [15], with which thrombus formation becomes more intensified. The poor outcomes and prognosis of CSVT are associated with, age, gender, and medical conditions [15].

Cases from our reports have different neurological manifestations after the previous episode of upper respiratory tract symptoms with confirmed SARS-CoV-2 infection from nasopharyngeal swab rt-PCR. SARS-CoV-2 is transmitted mostly through respiratory droplets and infected the lungs [17]. The entry of SARS-CoV-2 into the human host cells relies on the surface angiotensin-converting enzyme 2 (ACE2), which is most expressed in the type II surfactant-secreting alveolar cells of the lungs [18]. The incubation period is approximately 4–5 days before the onset of symptoms [19, 20]. Almost all patients with COVID-19 have lung problems, such as cough, shortness of breath, or ARDS [19]. Guan and colleagues reported that the clinical outcomes of COVID-19 can be predicted by the amount of comorbidities for example hypertension, diabetes mellitus, cardiovascular disease, stroke, smoking, and age more than years old [21]. The first patient had two comorbidities of hypertension and diabetes mellitus, while the second patient has age > 60 years old as comorbid.

SARS-CoV-2 infection activates disproportionate inflammatory innate and adaptive immune response [22]. The interleukin (IL)-1β, IL-6, IL-12, interferon γ (IFN-γ), IFN-γ-inducible protein 10 (IP10), and monocyte chemoattractant protein (MCP) were associated with pulmonary inflammation and extensive lung damage in SARS-CoV-2 patients [23]. Both patients had severe pneumonia with GGO in their thorax CT scan. The worse clinical experience in the second patient was most likely the result of this immunity instability. Furthermore, elderly patients are more susceptible to being worsened against viral infections, due to decreased interferon production [24]. SARS-CoV-2 is known to suppress the induction of antiviral type I interferon (IFN-α/β) [24].

“Cytokine storm” has been a major cause of severe COVID-19 with high levels of inflammatory markers found in the blood (C-reactive protein, ferritin, and D-dimers) [25, 26]. Hematologic examination in severe COVID-19 showed lymphocytopenia and an increased sum of neutrophils (NEU) [27]. Neutrophils are activated and migrated to the infected. Elevation of the NLR predicts the adverse prognostic in COVID-19 patients [28]. Both patients had NLR of more than 5, especially the second patient had twofold NLR than the first patient. Extremely high leukocyte level is a bad predictor in the second patient. NEU induces DNA cell damage by releasing reactive oxygen species [28]. A study published by Huang and colleagues reported leukocytosis 2.0 rise and neutrophilia 4.4-fold rise [29] as predictor severity of the disease. This may be confused in myeloproliferative neoplasm (MPN), but we did not do the blood film examination to exclude the disease in this patient. The pathogenesis of thrombosis in MPN is related to an increase in blood cell counts (leukocytosis, erythrocytosis, and thrombocytosis) and the presence of JAK2 mutation. Patients with WBC > 15 × 109/L was a significant predictor for thrombosis [30].

Clinically, relevant hemostatic changes occur 50–70% in septic patients, with 35% meeting the criteria of disseminated intravascular coagulation [31]. Furthermore, patients with COVID-19 have diffused inflammation, which activates the coagulation system by consuming clotting factors and resulting in DIC [32]. The systemic infection of SARS-CoV-2 damages the endothelial cells, activates mononuclear cells, produces proinflammatory cytokines, and promotes coagulation [33]. Thrombin elicits the production of chemoattractant proteins, in monocytes, fibroblasts, mesothelial, and vascular endothelial cells, by interacting with protease-activated receptors (PARs) 1,3, and 4 [31]. PARs are transmembrane G-protein coupled receptors that have their functions from 1–4 [34]. The PARs 1, 3, and 4 are receptors activated by thrombin. Through PAR2, factor Xa and the tissue factor (VIIa) complex also upregulate chemoattractant proteins (IL-6, IL-8) in vascular endothelial cells [31]. The tissue factor (VIIa) catalyzes the conversion of factor X to Xa, forming prothrombinase complex with factor Va, prothrombin factor (II), and calcium, which results in generating thrombin factor (IIa) [32]. The physiological anticoagulant mechanisms and fibrinolysis inhibited by endothelial cells cause intravascular fibrin deposition [31].

The mortality rate in CSVT is 1% at discharge and continuing to decrease with the use of anticoagulant treatment [14]. The main cause of early death after acute CSVT is secondary trans-tentorial herniation, due to multiple lesions to diffuse brain edema [15]. Other causes are status epilepticus, medical complications, and pulmonary embolism [15]. According to the laboratory and thorax CTA results, the second patient had pulmonary embolism and thrombosis at the same time (Table 1).

The difference of the clinical presentation’s severity in both patients was also determined by the location of vein thrombosis and the brain edema. The first patient presented better clinical manifestation, because the edema was in the supratentorial brain area, while the second exhibited worse symptoms due to involvement of infratentorial brain edema (cerebellum and pons). Head NCCT scan of the second case showed direct signs of dense triangle sign (Fig. 2B white arrow) and cord at right TS (Fig. 2C white arrow). Furthermore, the CTV of the first patient showed a filling defect at bilateral TS and SSS (Fig. 1E, F white arrows). During the COVID-19 pandemic, CTV was preferred over MRI because it is an accurate and more rapid technique to detect cerebral venous thrombosis [35]. The massive thrombosis and emboli in the lungs were the consequences of the hypercoagulable state and body immobility. Thrombosis makes up 31% of thrombotic complications in ICU patients down with COVID-19 [36]. The second patient had late thrombosis complications although had been administered by heparin, which might be related to this immobilized condition and high level of D-dimer in the first presentation.

Critically ill patients develop a hypercoagulable state due to immobilization, mechanical ventilation, central venous access devices, and nutritional deficiencies [37]. COVID-19 and hypercoagulability are further implicating the risks of pulmonary embolism (PE), vein thromboembolism (VTE), disseminated intravascular coagulation (DIC), and stroke [38]. The dysfunction of endothelial cells plays role in thrombin generation and fibrinolysis shutdown [34]. The second patient had a more severe condition, because of being hospitalized with a ventilator, central venous catheter, and immobilized for 10 days.

Pro-coagulation state in COVID-19 generates CSVT. Hypercoagulability of SARS-CoV-2 serves as an increase in, D-dimer, LDH, fibrinogen, factor VIII (FVIII), von Willebrand factor (vWF), and decreased antithrombin [39]. Patients with severe pneumonia, especially ARDS, have low oxygen concentration that increases blood viscosity, while also inducing the hypoxia-inducible transcription factor-dependent signaling pathway [36]. After the COVID-19 swab had been negative, the second patient was observed to develop massive thrombosis. The second patient had more D-dimer levels than the first, and the length of treatment was longer. Furthermore, the thrombosis process was still ongoing even though COVID-19 was negative and the D-dimer level was decreased. It was a challenge to observe whether the second patient had the previous thrombosis or not, with a diagnostic approach taken in checking for D-dimer and heart thrombosis [40]. Therefore, it was concluded that this patient had brain, heart, and pulmonary thrombosis.

Three important physiological anticoagulant pathways are the antithrombin, the activated protein C, and tissue factor inhibitor (TFPI) system. Those pathways are deranging in sepsis, which is precipitated by cytokines [34]. In sepsis, a high level of cytokines is found in the circulation, with hemostatic activation mediated by TNF. The expression of tissue factor in mononuclear cells and subsequent exposure to blood results in thrombin generation, accompanied by fibrinogen to fibrin conversion. The interaction and activation of platelets and their walls contribute to microvascular clot formation [34].

The anticoagulant commonly used in preventing DIC and VTE is low molecular weight heparin (LMWH) because it has an anti-inflammatory effect [41]. The first patient was given LMWH, to minimalize the contact with the patient. The D-dimer was diagnosed after 4 days and observed to be decreased, with improvement in neurological manifestation. Due to being in ICU, heparin was intravenously administered to the second patient, to pay close attention to the APTT. Heparin interacts with pro-inflammatory and procoagulant cascades, to prevent inflammation, and coagulopathy associated with sepsis [41]. Unfractionated heparin and LMWH are mostly used, in the cases of acute CSVT [9]. Tissue-plasminogen activator (tPA), in fibrinolytic therapy, is used in patients with low compensating conditions and resilient from prior anticoagulant [42]. The second patient was given fibrinolytic therapy the following day, after the diagnosis of CSVT. Due to multiple organ failures and loss of consciousness, it was therefore concluded that the response was poor.


CSVT is one of the neurological complications of COVID-19 manifestation, possessing a grave prognosis when the brainstem venous drainage is involved. Hypercoagulability is also a complication of this disease, in patients with previous comorbid hypertension and diabetes mellitus. Thrombogenesis and coagulation cascades are prolonged, despite successful alteration to the negative result of SARS-CoV-2, through the use of the rt-PCR test. When monitoring neutrophil and lymphocyte ratio (NLR), it was observed that D-dimer level, fibrinogen, and CRP are bad prognosis indicators. Therefore, the use of heparin or LMWH decreases the D-dimer and not by any means increase the symptoms.

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.



Angiotensin-converting enzyme 2


Activated partial thromboplastin time


Acute respiratory distress syndrome


Blood urea nitrogen


Creatinine kinase myocardial band


Coronavirus disease 2019


C-reactive protein


Cerebral sinus venous thrombosis


Computed tomography


CT angiography


CT venography


Disseminated intravascular coagulation


Erythrocyte sedimentation rate


Factor VIII


Ground glass opacity


Hemoglobin A1c


Head contrast computed tomography


Intensive care unit






Inducible protein 10


Index normalized ratio


Lactate dehydrogenase


Low molecular weight heparin


Monocyte chemoattractant protein




Neutrophil to lymphocyte


Protease-activated receptors


Pulmonary embolism


Prothrombin time


Severe acute respiratory syndrome coronavirus 2


Serum glutamic oxaloacetic transaminase


Serum glutamic pyruvic transaminase


Superior sagittal sinus


Tissue factor inhibitor


Tissue-plasminogen activator


Transverse sinus


Vein thromboembolism


von Willebrand factor


White blood cells


  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020;133(9):1025–31.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–90.

    Article  PubMed  Google Scholar 

  6. Katz JM, Libman RB, Wang JJ, Sanelli P, Filippi CG, Gribko M, et al. Cerebrovascular complications of COVID-19. Stroke. 2020;51(9):e227–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cavalcanti DD, Raz E, Shapiro M, Dehkharghani S, Yaghi S, Lillemoe K, et al. Cerebral venous thrombosis associated with COVID-19. AJNR Am J Neuroradiol. 2020;41(8):1370–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Garaci F, Di Giuliano F, Picchi E, Da Ros V, Floris R. Venous cerebral thrombosis in COVID-19 patient. J Neurol Sci. 2020;414:116871.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Klein DE, Libman R, Kirsch C, Arora R. Cerebral venous thrombosis: a typical presentation of COVID-19 in the young. J Stroke Cerebrovasc Dis. 2020;29(8):104989.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998–1000.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Devasagayam S, Wyatt B, Leyden J, Kleinig T. Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study. Stroke. 2016;47(9):2180–2.

    Article  PubMed  Google Scholar 

  14. Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke. 2012;43(12):3375–7.

    Article  PubMed  Google Scholar 

  15. Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158–92.

    Article  PubMed  Google Scholar 

  16. Dmytriw AA, Song JSA, Yu E, Poon CS. Cerebral venous thrombosis: state of the art diagnosis and management. Neuroradiology. 2018;60(7):669–85.

    Article  PubMed  Google Scholar 

  17. Hui KPY, Cheung MC, Perera RAPM, Ng KC, Bui CHT, Ho JCW, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir Med. 2020;8(7):687–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127–0.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.

    Article  CAS  PubMed  Google Scholar 

  20. Pung R, Chiew CJ, Young BE, Chin S, Chen MI, Clapham HE, et al. Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. Lancet. 2020;395(10229):1039–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther. 2020;5(1):84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Rao VUS, Arakeri G, Subash A, Rao J, Jadhav S, Suhail Sayeed M, et al. COVID-19: Loss of bridging between innate and adaptive immunity? Med Hypotheses. 2020;144:109861.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan , China. Lancet. 2020;395(10223):497–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Arachchillage DRJ, Laffan M. Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms. Semin Thromb Hemost. 2019;45(6):604–11.

    Article  CAS  PubMed  Google Scholar 

  31. Okamoto K, Tamura T, Sawatsubashi Y. Sepsis and disseminated intravascular coagulation. J Intensive Care. 2016;4(1):23.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26–34.

    Article  CAS  PubMed  Google Scholar 

  33. Levi M, van der Poll T, ten Cate H, van Deventer SJ. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest. 1997;27(1):3–9.

    Article  CAS  PubMed  Google Scholar 

  34. Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38–44.

    Article  CAS  PubMed  Google Scholar 

  35. Leach JL, Fortuna RB, Jones BV, Gaskill-Shipley MF. Imaging of cerebral venous thrombosis: current techniques, spectrum of findings, and diagnostic pitfalls. Radiographics. 2006;26(Suppl 1):S19–43.

    Article  PubMed  Google Scholar 

  36. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020;382(17):e38.

    Article  PubMed  Google Scholar 

  39. Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost. 2020;120(5):876–8.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Tal S, Spectre G, Kornowski R, Perl L. Venous thromboembolism complicated with COVID-19: what do we know so far? Acta Haematol. 2020;143(5):417–24.

    Article  CAS  PubMed  Google Scholar 

  41. Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagulant: do heparins have direct anti-inflammatory effects? Thromb Haemost. 2017;117(3):437–44.

    Article  PubMed  Google Scholar 

  42. Barrett CD, Moore HB, Moore EE, McIntyre RC, Moore PK, Burke J, et al. Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: scientific rationale and review. Res Pract Thromb Haemost. 2020;4(4):524–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


All the doctors, nurses, and staffs who have contributed to fight COVID-19 in our Hospital with a sincere heart.


No funding to report

Author information

Authors and Affiliations



All authors contributed significantly to the manuscript writing and designing. “All authors have read and approved the manuscript.” PAS: writing the manuscript and designing the case report. KT: writing and designing the case report. NMS: literature reviewing and reviewing the manuscript. IASW: literature reviewing and reviewing the manuscript. PUD: literature reviewing and reviewing the manuscript. DPGPS: reviewing the manuscript and approving the manuscript. Criticizing the content and structure of the manuscript.

Corresponding author

Correspondence to Prysta Aderlia Sitanggang.

Ethics declarations

Ethics approval and consent to participate

All procedures performed in the study were in accordance with the ethical standards of the Research Ethics Committee Faculty of Medicine, Udayana University/Sanglah Hospital Denpasar. We obtained approval from research ethics committee no. 2084/UN14.2.2.VII.14/LT/2020 on 19 October 2020.

Consent for publication

A written informed consent was obtained from the legal guardian of the patients and all contributors for publication. We obtained approval from research ethics committee no. 2084/UN14.2.2.VII.14/LT/2020 on 19 October 2020.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sitanggang, P.A., Tini, K., Susilawathi, N.M. et al. Case reports of cerebral sinus venous thrombosis in COVID-19 patients. Egypt J Neurol Psychiatry Neurosurg 57, 83 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: